Filing Details
- Accession Number:
- 0000904454-17-000501
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-07-06 16:49:22
- Reporting Period:
- 2017-07-03
- Filing Date:
- 2017-07-06
- Accepted Time:
- 2017-07-06 16:49:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178711 | Paratek Pharmaceuticals Inc. | PRTK | Pharmaceutical Preparations (2834) | 330960223 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1524372 | M. William Haskel | C/O Paratek Pharmaceuticals, Inc. 75 Park Plaza, 4Th Floor Boston MA 02116 | Sr. Vp, Sec. & General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-07-03 | 7,000 | $0.00 | 39,000 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2017-07-05 | 2,461 | $23.58 | 36,539 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Footnotes
- Represents performance-based restricted stock units granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on July 3, 2017.
- Sale of shares to cover personal income tax obligations upon vesting of performance-based restricted stock units, pursuant to Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $23.90, inclusive. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Billionaire Hedge Funds
